The first malaria treatment specifically developed for newborn babies and young infants has been approved for use.   The approval, by Switzerland’s medical agency Swissmedic, of Coartem Baby ...

Kenya is among eight African countries that participated in clinical trials for a newly approved malaria treatment, ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

Novartis has received approval for Coartem Baby, the world's first malaria treatment specifically for newborns and young ...

In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Hold rating on Novartis, with a price target of $108.00. The company’s shares closed yesterday at $122.94. According to ...

Switzerland’s health regulator Swissmedic granted marketing authorisation on Tuesday for Novartis Riamet Baby, also known as ...

Players in the health sector have commended the approval of the first-ever malaria drug for babies weighing less than five ...

Swissmedic approves Novartis’ Coartem Baby to treat malaria in newborns and young infants: Basel Thursday, July 10, 2025, 11:00 Hrs [IST] Novartis announced Coartem (artemether- ...

CHENNAI: Swiss-pharma major Novartis AG said early this week that its pediatric malaria treatment, Coartem Baby, received ...

A new treatment for malaria in babies and very small children has just been approved; we hear more about the drug expected to save many lives.

In a major breakthrough, the first-ever treatment for malaria has been approved for newborns and infants under 11 ...